Abstract:BACKGROUND & AIMS:Hepatic ischaemia-reperfusion (I/R) injury is characterised by severe inflammation and extensive cell death. Multiple signalling pathways, including NF-κB and mitogen-activated protein kinase (MAPK)/c-Jun NH2-terminal kinase (JNK), have important roles in this process. Identifying the unknown critical regulators of these signalling pathways could provide potential targets for therapeutic application. Dual-specificity phosphatase 14 (DUSP14) acts as a negative regulator of NF-κB signalling. However, its function in hepatic I/R injury is unknown. METHODS:Hepatocyte-specific Dusp14 knockout (HKO) and transgenic (TG) mice were subjected to hepatic I/R surgery to examine Dusp14 function in vivo. Primary hepatocytes isolated from Dusp14-HKO and Dusp14-TG mice were cultured and subjected to hypoxia/reoxygenation insult in vitro. Inflammatory cytokine production was measured using quantitative reverse transcription PCR and ELISA. Liver damage was analysed using histopathology. Co-immunoprecipitation and pull-down assays followed by Western blot were performed to detect Dusp14 and transforming growth factor (Tgf)-β-activated kinase 1 (Tak1) interactions. RESULTS:Dusp14 was significantly downregulated in liver tissues from liver transplantation patients and mice subjected to hepatic I/R surgery. Dusp14-HKO and Dusp14-TG mouse models demonstrated that Dusp14 reduced cell death, ameliorated inflammation, and promoted hepatocyte proliferation and/or regeneration. Dusp14 also suppressed NF-κB and MAPK signalling via a physical interaction with Tak1, leading to its subsequent inhibition. Tak1 inhibition by 5Z-7-ox abolished Dusp14 function in vivo, indicating that TAK1 is required for Dusp14 function in hepatic I/R injury. Finally, mutant Dusp14 lost the ability to bind Tak1 and failed to protect against hepatic I/R injury. CONCLUSIONS:Dusp14 is a protective factor in hepatic I/R injury, and the Dusp14-Tak1-Jnk1/2 regulatory axis is important for the pathogenesis of hepatic I/R injury. Modulation of this axis could be a novel therapeutic strategy to prevent or interfere with this pathological process. LAY SUMMARY:Reductions in the level of the protein Dusp14 are closely associated with liver damage caused by inadequate blood supply followed by restoration of blood flow to the liver. Dusp14 protects against liver damage by suppressing the activity of Tak1. Targeting Dusp14 could be a strategy for prevention and treatment of this disease.

Ubiquitin-specific protease 29 attenuates hepatic ischemia-reperfusion injury by mediating TGF-β-activated kinase 1 deubiquitination

Ubiquitin-Specific Peptidase 10 Protects Against Hepatic Ischaemic/Reperfusion Injury via TAK1 Signalling

Ubiquitin-Specific Protease 29 Exacerbates Cerebral Ischemia-Reperfusion Injury in Mice.

Ubiquitin-specific Protease 11 Aggravates Ischemia-reperfusion-induced Cardiomyocyte Pyroptosis and Injury by Promoting TRAF3 Deubiquitination

Mitogen Activated Protein Kinase Phosphatase 5 Alleviates Liver Ischemia–reperfusion Injury by Inhibiting TAK1/JNK/p38 Pathway

Dusp14 protects against hepatic ischaemia-reperfusion injury via Tak1 suppression.

Tripartite Motif‐Containing 27 Attenuates Liver Ischemia/Reperfusion Injury by Suppressing Transforming Growth Factor β–Activated Kinase 1 (TAK1) by TAK1 Binding Protein 2/3 Degradation

Activation of Cyclic Adenosine Monophosphate-Dependent Protein Kinase a Signaling Prevents Liver Ischemia/reperfusion Injury in Mice

Effect of Deubiquitinase USP8 on Hypoxia/reoxygenation‑induced Inflammation by Deubiquitination of TAK1 in Renal Tubular Epithelial Cells.

Genetic and pharmacological targeting of XBP1 alleviates hepatic ischemia reperfusion injury by enhancing FoxO1-dependent mitophagy

Sphingosine Kinase 1 Knockout Alleviates Hepatic Ischemia/reperfusion Injury by Attenuating Inflammation and Oxidative Stress in Mice.

Inhibition of Usp14 ameliorates renal ischemia-reperfusion injury by reducing Tfap2a stabilization and facilitating mitophagy

Deubiquitinase USP18 inhibits hepatic stellate cells activation and alleviates liver fibrosis via regulation of TAK1 activity

USP15 Regulates P66shc Stability Associated with Drp1 Activation in Liver Ischemia/reperfusion

USP19 Stabilizes TAK1 to Regulate High Glucose/Free Fatty Acid-induced Dysfunction in HK-2 Cells

Blockade of Hepatocyte PCSK9 Ameliorates Hepatic Ischemia-Reperfusion Injury by Promoting Pink1-Parkin–Mediated Mitophagy

USP9x Promotes CD8 + T-cell Dysfunction in Association with Autophagy Inhibition in Septic Liver Injury.

USP18 protects against hepatic steatosis and insulin resistance via its DUB activity.

Usp49 Inhibits Ischemia-Reperfusion-Induced Cell Viability Suppression And Apoptosis In Human Ac16 Cardiomyocytes Through Dusp1-Jnk1/2 Signaling

Regulator of G‐protein signaling 14 protects the liver from ischemia–reperfusion injury by suppressing TGF‐β‐activated kinase 1 activation